Clinical trials

Clinical trial intelligence

Per-cancer measures of registered clinical research: activity, growth, enrollment, who sponsors it and where it runs, how often it stops, and how it compares with the disease burden. Every figure is computed from ClinicalTrials.gov records with a versioned formula; nothing here is an observation.

Top-level cancers: 36
Interventional studies: 68,117
Active: 19,890
Recruiting: 10,793
Phase III active: 2,355
Phase III recruiting: 1,208

clinicaltrialsComputed36 entities · sorted by Active (desc) · click a header to sort

Cancer	Total	Active	Recruiting	Ph III active / recruiting	Growth YoY	Avg enrollment	Industry share	Sponsor HHI · top sponsor	Countries · US share	Termination share

Computedformula ci-trial-intel-v1· interventional studies only · aggregation over NCIt descendants (depth ≤ 12)· active = RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING

Thresholds: growth requires ≥ 20 studies in the prior window (windows 2025-09-29 → 2026-09-29 vs 2024-09-29 → 2025-09-29); sponsor HHI requires ≥ 10 active studies; termination share requires ≥ 30 terminal studies first posted since 2010-01-01; burden ratios require ≥ 100 annual deaths (USA, latest year with both counts from one source: cdc-uscs). A multinational study contributes to every country it lists, so country shares can sum above 100%. Methodology

Data updated 16 hours agoSource updated unknowncomputed by CancerIndex from ClinicalTrials.gov records

Malignant Lung Neoplasm	8,854	2,644	1,428	382 / 179	+8.1%	794	37%	0.004AstraZeneca	80 · 41%	34.8%	20.1USA 2023cdc-uscs
Malignant Breast Neoplasm	9,637	2,627	1,396	320 / 150	+23%	949	18%	0.006Fudan University	90 · 44%	25.6%	61.5USA 2023cdc-uscs
Non-Hodgkin Lymphoma	7,064	2,168	1,128	252 / 115	+9.4%	172	27%	0.009National Cancer Institute (NCI)	72 · 53%	35.5%	108.5USA 2023cdc-uscs
Leukemia	7,072	1,769	1,011	190 / 99	−2%	155	19%	0.012M.D. Anderson Cancer Center	73 · 54%	35.6%	75USA 2023cdc-uscs
Malignant Prostate Neoplasm	4,824	1,375	744	148 / 79	+22.9%	465	18%	0.005M.D. Anderson Cancer Center	68 · 55%	27.1%	40.6USA 2023cdc-uscs
Malignant Liver Neoplasm	3,146	906	530	94 / 46	+5.5%	1,392	21%	0.008Sun Yat-sen University	70 · 29%	32.5%	30.3USA 2023cdc-uscs
Malignant Pancreatic Neoplasm	2,956	904	506	69 / 46	+21.9%	1,659	32%	0.005National Cancer Institute (NCI)	52 · 47%	34.5%	18.3USA 2023cdc-uscs
Malignant Central Nervous System Neoplasm	2,459	823	453	47 / 27	+21.8%	93	16%	0.008National Cancer Institute (NCI)	38 · 58%	34.9%	45.2USA 2023cdc-uscs
Multiple Myeloma	2,885	814	414	115 / 54	+13.3%	158	29%	0.012National Cancer Institute (NCI)	60 · 54%	34%	70.3USA 2023cdc-uscs
Malignant Ovarian Neoplasm	2,529	684	385	89 / 46	+9.8%	510	37%	0.01National Cancer Institute (NCI)	61 · 54%	32.8%	53.1USA 2023cdc-uscs
Malignant Gastric Neoplasm	2,175	652	351	78 / 49	+15.1%	1,978	26%	0.007Fudan University	52 · 31%	26.2%	59.5USA 2023cdc-uscs
Malignant Esophageal Neoplasm	1,535	518	301	69 / 41	+4.1%	2,302	23%	0.008National Cancer Institute (NCI)	53 · 32%	28.5%	32.3USA 2023cdc-uscs
Malignant Cervical Neoplasm	1,576	505	279	59 / 34	−12.7%	2,217	20%	0.012National Cancer Institute (NCI)	72 · 42%	22.7%	121.3USA 2023cdc-uscs
Malignant Kidney Neoplasm	1,721	453	231	46 / 18	+7.4%	255	29%	0.015M.D. Anderson Cancer Center	55 · 63%	38.3%	30.7USA 2023cdc-uscs
Malignant Uterine Corpus Neoplasm	1,223	411	226	41 / 25	+3.1%	247	31%	0.011National Cancer Institute (NCI)	56 · 60%	27.6%	50.2USA 2023cdc-uscs
Malignant Rectal Neoplasm	1,184	386	215	57 / 36	+9.8%	629	5%	0.01Fudan University	44 · 24%	28%	29.9USA 2023cdc-uscs
Malignant Bladder Neoplasm	1,143	346	177	48 / 23	+17.9%	323	21%	0.013National Cancer Institute (NCI)	58 · 57%	31.3%	20USA 2023cdc-uscs
Malignant Nasopharyngeal Neoplasm	642	261	139	97 / 56	+5.2%	557	9%	0.135Sun Yat-sen University	21 · 11%	24.1%	376.6USA 2023cdc-uscs
Malignant Colon Neoplasm	910	225	117	32 / 18	−3.8%	1,314	14%	0.011M.D. Anderson Cancer Center	44 · 38%	26.9%	5.5USA 2023cdc-uscs
Hodgkin Lymphoma	829	179	90	12 / 6	−4.2%	110	11%	0.023City of Hope Medical Center	39 · 68%	27.7%	175.3USA 2023cdc-uscs
Malignant Thyroid Gland Neoplasm	519	176	92	15 / 12	+4.9%	197	13%	0.019M.D. Anderson Cancer Center	39 · 48%	25.9%	81.9USA 2023cdc-uscs
Malignant Lip and Oral Cavity Neoplasm	417	149	77	17 / 11	+9.8%	161	5%	0.025National Cancer Institute (NCI)	24 · 48%	26.3%	—
Malignant Oropharyngeal Neoplasm	379	143	77	15 / 7	−7.7%	269	6%	0.026National Cancer Institute (NCI)	27 · 66%	34.4%	—
Skin Carcinoma	316	127	69	14 / 8	+12%	180	20%	0.02National Cancer Institute (NCI)	43 · 68%	35.3%	—
Malignant Mesothelioma	412	96	55	2 / 1	—	135	38%	0.027National Cancer Institute (NCI)	32 · 60%	37.4%	45.1USA 2023cdc-uscs
Cutaneous Melanoma	206	78	39	6 / 3	—	219	27%	0.039National Cancer Institute (NCI)	31 · 71%	36.1%	9.3USA 2023cdc-uscs
Malignant Anal Neoplasm	180	68	34	7 / 2	—	667	15%	0.023National Cancer Institute (NCI)	27 · 51%	27.1%	42.5USA 2023cdc-uscs
Malignant Laryngeal Neoplasm	218	66	41	9 / 5	—	130	2%	0.071National Cancer Institute (NCI)	16 · 71%	34.1%	16.9USA 2023cdc-uscs
Malignant Salivary Gland Neoplasm	205	63	32	2 / 0	—	169	19%	0.046National Cancer Institute (NCI)	23 · 71%	21.4%	56.6USA 2023cdc-uscs
Malignant Vulvar Neoplasm	142	54	32	2 / 1	—	330	19%	0.025National Cancer Institute (NCI)	23 · 54%	21.3%	36.6USA 2023cdc-uscs
Malignant Hypopharyngeal Neoplasm	175	53	31	9 / 5	—	136	0%	0.094National Cancer Institute (NCI)	14 · 62%	41.4%	109.7USA 2023cdc-uscs
Malignant Penile Neoplasm	82	43	22	2 / 0	—	324	14%	0.052National Cancer Institute (NCI)	13 · 47%	—	120.1USA 2023cdc-uscs
Malignant Testicular Neoplasm	133	43	26	3 / 3	—	415	2%	0.038University Health Network, Toronto	18 · 56%	35.3%	80.1USA 2023cdc-uscs
Malignant Gallbladder Neoplasm	160	32	14	3 / 1	—	136	6%	0.057National Cancer Institute (NCI)	8 · 53%	27.1%	—
Malignant Vaginal Neoplasm	101	31	20	3 / 2	—	424	19%	0.053National Cancer Institute (NCI)	10 · 68%	29.3%	70.8USA 2023cdc-uscs
Kaposi Sarcoma	108	18	11	1 / 0	—	286	0%	0.228National Cancer Institute (NCI)	9 · 61%	—	—